Shanghai Fosun Pharmaceutical Announces Poll Results on Spin-off and Listing of Fosun Adgenvax

Key Highlights from the 2026 First Extraordinary General Meeting and Shareholders’ Class Meetings

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Stock Code: 02196) has published the poll results of its 2026 first extraordinary general meeting (EGM), alongside the A Shareholders’ and H Shareholders’ class meetings held on February 27, 2026 in Shanghai. The focus of these meetings was the proposed spin-off and listing of its subsidiary, Fosun Adgenvax, on the Main Board of the Hong Kong Stock Exchange.

Key Points Investors Need to Know

• Approval of Fosun Adgenvax Spin-off: All major resolutions related to the proposed spin-off and Hong Kong listing of Fosun Adgenvax were overwhelmingly approved at the EGM, with over 99% of votes in favor, including those from minority shareholders. This indicates a strong mandate from investors for the company’s strategic direction.
• Assured Entitlements for H Shareholders: A special resolution regarding the provision of assured entitlements to H Shareholders in connection with the spin-off was approved at the EGM and H Shareholders’ Class Meeting, but failed to gain approval at the A Shareholders’ Class Meeting due to insufficient support from minority A shareholders.
• Impact on Shareholders: As the assured entitlements resolution did not pass all required meetings, no assured entitlements will be provided to either A or H shareholders for the Fosun Adgenvax spin-off. Importantly, the company clarified that this outcome does not affect the implementation of the proposed spin-off listing.
• Compliance and Legal Validity: The meetings, voting processes, and results have been certified as legally valid by the company’s PRC legal advisers, Grandall Law Firm (Shanghai).

Detailed Breakdown of the Voting Results

1. Attendance and Voting Power

• Total issued shares: 2,670,429,325 (2,118,488,825 A Shares and 551,940,500 H Shares).
• EGM attendance: 1,110,294,633 shares (42.06% of total shares), with 1,560 A shareholders and 2 H shareholders or their proxies present.
• A Shareholders’ Class Meeting: 966,487,915 A shares (46.05% of total A shares) voted.
• H Shareholders’ Class Meeting: 143,794,718 H shares (26.58% of total H shares) voted.

2. Resolutions Passed at the EGM

• Spin-off Compliance and Plan: Resolutions confirming compliance with legal and regulatory requirements, the plan for the spin-off and listing, and the commercial rationale for the transaction were all passed with >99% support.
• Operational Independence and Standardization: Resolutions affirming Fosun Adgenvax’s operational independence, compliance, and capability for standardized operations also passed with over 99% support.
• Protection of Shareholder and Creditor Interests: The EGM approved the resolution asserting that the spin-off will safeguard the legitimate rights and interests of both shareholders and creditors.
• Directors’ and Senior Management Interests: Those directors and executives with interests in the spin-off (owning 817,932 A shares and 65,000 H shares collectively) abstained from voting on the related resolution, which nevertheless passed with the required majority.
• Authorisation to the Board: The Board received authorisation to handle all matters related to the spin-off and listing.
• Assured Entitlements Resolution: While the EGM and H Shareholders’ Class Meeting approved the provision of assured entitlements to H shareholders, the resolution was defeated at the A Shareholders’ Class Meeting by minority shareholders.

3. Price-Sensitive and Shareholder-Relevant Developments

• Failure of Assured Entitlements Resolution at A Shareholders’ Class Meeting: The resolution regarding the provision of assured entitlements to H shareholders in the Fosun Adgenvax spin-off failed to receive the required two-thirds support from minority A shareholders. As a result, no assured entitlements will be provided to any shareholders in the spin-off.
• No Impact on Spin-off Implementation: The company clarified that the lack of assured entitlements will not hinder or delay the Fosun Adgenvax spin-off and listing on the Hong Kong Stock Exchange.
• Potential Market Impact: The approval of the spin-off itself is a significant corporate action and may be viewed as a positive catalyst for Fosun Pharma’s valuation, given that successful spin-offs can unlock shareholder value. However, the absence of assured entitlements for shareholders (especially H shareholders) may be seen as a negative by investors seeking direct participation in the new listing.

Governance and Compliance

• The EGM and class meetings were duly convened and conducted in accordance with the Company Law, the Articles of Association, and Hong Kong Listing Rules, with independent legal and professional supervision of the voting process.
• BDO Limited acted as scrutineers, and Grandall Law Firm (Shanghai) certified the validity of the meetings and poll results.

Board and Management

• The meetings were chaired by Mr. Chen Yuqing, Chairman of the Board.
• Six of the twelve directors were present, including four executive directors and two independent non-executive directors.

What Investors Should Watch

• Spin-off Execution: Investors should monitor the timeline and final implementation of the Fosun Adgenvax listing, as this strategic move could significantly impact Fosun Pharma’s business structure and valuation.
• No Direct Spin-off Allotment: The absence of assured entitlements means shareholders will not automatically receive shares or rights in the new entity, which could influence market expectations and share price performance around the spin-off.
• Regulatory and Market Sentiment: While the spin-off is proceeding, the mixed shareholder support (especially from minority A holders) suggests underlying sentiment that investors should consider in their risk assessment.

Conclusion

The approval of the Fosun Adgenvax spin-off and listing is a major strategic milestone for Shanghai Fosun Pharmaceutical, potentially unlocking value for the company and its shareholders. However, the failure to pass assured entitlements for shareholders introduces uncertainty regarding direct participation in the new listing. Investors should stay alert to further announcements from the company concerning the timeline and details of the spin-off execution.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult professional advisers before making investment decisions. The information herein is based on the company’s public announcement dated February 27, 2026. Market conditions and company circumstances may change after publication.

View FOSUN PHARMA Historical chart here